Compound and method for treating diseases and disorders

Abstract

Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

What is claimed is: 
     
         1 . A method for treating a disease, state or disorder in a non-human animal, comprising an act of:
 administering a cannabinoid-terpenoid solution (CTS) to an animal suffering from a disease, state or disorder, the CTS comprising two or more cannabinoids and one or more terpenes.   
     
     
         2 . The method as set forth in  claim 1 , wherein the CTS further comprise a lipophilic carrier mixed with the two or more cannabinoids and the one or more terpenes. 
     
     
         3 . The method as set forth in  claim 1 , wherein the disease, state, or disorder is selected from a group consisting of epilepsy, anxiety, pain, inflammation, degenerative myelopathy, Parkinson's disease, lameness and gait issues, elbow dysplasia, hip dysplasia, back and hind leg problems, arthritis, seizures, encephalopathy, lethargy, focus/attentional problems, and cognitive issues, spasticity, cancer, glioblastoma, weakness, numbness, mood disorders, hypertension, tremors, peripheral neuropathy, bowel and bladder control issues, inactivity, poor appetite, tumors, Cushing's disease, aggressive behavior, pruritis, dermatitis, vomiting, nausea, glaucoma, noise aversion, dystonia, personality change, restlessness, inflammatory bowel syndrome, and neurological damage. 
     
     
         4 . A method for treating seizures in a non-human animal, comprising:
 administering a cannabinoid-terpenoid medicament CTS to an animal suffering from seizures, the cannabinoid-terpenoid medicament CTS comprising two or more cannabinoids and one or more terpenes.   
     
     
         5 . The method as set forth in  claim 4 , wherein the CTS further comprises a lipophilic carrier mixed with the two or more cannabinoids and the one or more terpenes. 
     
     
         6 . The method as set forth in  claim 4 , wherein the CBD comprises between 7 percent and 30 percent of the CTS and the THC comprises between 1 and 10 percent of the CTS. 
     
     
         7 . The method as set forth in  claim 4 , wherein the CBD comprises between 8 percent and 12 percent of the CTS and the THC comprises between 2 percent and 4 percent of the CTS. 
     
     
         8 . The method as set forth in  claim 4 , wherein the one or more terpenes include one or more terpenes selected from a group consisting of Beta-Carophyllene, Linalool, D-Limonene, Beta-Mycene, Alpha-Pinene, Humulene, and Guaine, or any combination thereof, to collectively form between 10 percent and 20 percent of the CTS. 
     
     
         9 . The method as set forth in  claim 4 , wherein in administering the CTS to the animal, the CTS is administered in combination with one or more concomitant anti-epileptic drugs (AED). 
     
     
         10 . A method for treating anxiety in a non-human animal, comprising:
 administering a cannabinoid-terpenoid medicament CTS to an animal suffering from anxiety, the cannabinoid-terpenoid medicament CTS comprising two or more cannabinoids and one or more terpenoids.   
     
     
         11 . The method as set forth in  claim 10 , wherein the CTS further comprises a lipophilic carrier mixed with the two or more cannabinoids and the one or more terpenes. 
     
     
         12 . The method as set forth in  claim 10 , wherein the two or more cannabinoids include at least cannabidiol (CBD) and tetrahydrocannabinol (THC), such that CBD and THC are mixed within the CTS to form a CBD dominant ratio with respect to one another. 
     
     
         13 . The method as set forth in  claim 10 , wherein the CBD comprises between 7 percent and 15 percent of the CTS and the THC comprises between 0.1 and 10 percent of the CTS, thereby forming a CBD dominant compound. 
     
     
         14 . The method as set forth in  claim 10 , wherein the CBD comprises between 10 percent and 14 percent of the CTS and the THC comprises between 0.3 percent and 1 percent of the CTS, thereby forming a CBD dominant compound. 
     
     
         15 . The method as set forth in  claim 10 , wherein the one or more terpenoids include one or more terpenes selected from a group consisting of Beta-Carophyllene, Linalool, D-Limonene, Beta-Mycene, Alpha-Pinene, Humulene, and Guaine, or any combination thereof, to collectively form between 10 percent and 20 percent of the CTS. 
     
     
         16 . A method for treating pain and/or inflammation in a non-human animal, comprising:
 administering a cannabinoid-terpenoid medicament CTS to an animal suffering from pain or inflammation, the cannabinoid-terpenoid medicament CTS comprising two or more cannabinoids and one or more terpenes.   
     
     
         17 . The method as set forth in  claim 16 , wherein the CTS further comprises a lipophilic carrier mixed with the two or more cannabinoids and the one or more terpenes. 
     
     
         18 . The method as set forth in  claim 16 , wherein the two or more cannabinoids include at least cannabidiol (CBD) and tetrahydrocannabinol (THC), such that CBD and THC are mixed within the CTS to form a ration with respect to one another that is selected from a group consisting of CBD:THC balanced, THC rich, and THC dominant. 
     
     
         19 . The method as set forth in  claim 16 , wherein the one or more terpenes include one or more terpenes selected from a group consisting of Beta-Carophyllene, Linalool, D-Limonene, Beta-Myrcene, Alpha-Pinene, Humulene, and Guaine, or any combination thereof, to collectively form between 10 percent and 20 percent of the CTS. 
     
     
         20 . The method as set forth in  claim 16 , wherein in administering the CTS to the animal, the CTS is administered orally to allow for transmucosal or oro-mucosal delivery to be immediately absorbable by the animal to treat pain or inflammation.